Healthcare provider profile · identity verified

Summit Subhash Pandat, M.D.

Allopathic & Osteopathic Physicians|Internal Medicine|Clinical Cardiac Electrophysiology · O FALLON, IL · NPI 1922454099

Profile state: payments only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Summit Subhash Pandat, M.D. received $5,778.22 in general payments during 2025 across 71 reported records.

Medtronic, Inc. accounted for 37.9% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 28 associated products.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$5,778.22

71 reported records · 7 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported companyCanonical companyAmountShareRecordsYear
Medtronic, Inc. Medtronic, Inc.
exact · evidence 2025-07-22
$2,190.5637.9%282025
Biosense Webster, Inc. Unresolved — no canonical attribution shown $1,239.6021.4%162025
Boston Scientific Corporation Unresolved — no canonical attribution shown $901.7115.6%102025
Abbott Laboratories Unresolved — no canonical attribution shown $858.2014.8%122025
BIOTRONIK INC. Unresolved — no canonical attribution shown $426.607.4%32025
Ethicon US, LLC Unresolved — no canonical attribution shown $139.262.4%12025
CARDIVA MEDICAL, INC. Unresolved — no canonical attribution shown $22.290.4%12025

What were the payments for?

Payment categories

CategoryAmountRecords
Food and Beverage$3,298.3263
Grant$1,309.981
Travel and Lodging$982.426
Education$187.501

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported productTypeReported companyRelated amount*RecordsYear
CARTO 3
Normalized: carto 3
Device Biosense Webster, Inc. $845.93 10 2025
Source payment records
AMPLATZER AMULET
Normalized: amplatzer amulet
Device Abbott Laboratories $493.94 5 2025
Source payment records
FARAPULSE
Normalized: farapulse
Device Boston Scientific Corporation $412.18 4 2025
Source payment records
AZURE XT DR MRI SURESCAN
Normalized: azure xt dr mri surescan
Device Medtronic, Inc. $268.95 7 2025
Source payment records
General - Therapies
Normalized: general therapies
Device Boston Scientific Corporation $195.14 2 2025
Source payment records
VersaCross Access Solution
Normalized: versacross access solution
Device Boston Scientific Corporation $163.31 2 2025
Source payment records
AVEIR
Normalized: aveir
Device Abbott Laboratories $160.86 1 2025
Source payment records
QDOT MICRO
Normalized: qdot micro
Device Biosense Webster, Inc. $141.37 1 2025
Source payment records
DERMABOND PRINEO
Normalized: dermabond prineo
Device Ethicon US, LLC $139.26 1 2025
Source payment records
ETHICON
Normalized: ethicon
Device Ethicon US, LLC $139.26 1 2025
Source payment records
STRATAFIX
Normalized: stratafix
Device Ethicon US, LLC $139.26 1 2025
Source payment records
VISTASEAL
Normalized: vistaseal
Biological Ethicon US, LLC $139.26 1 2025
Source payment records
AURORA EV-ICD MRI SURESCAN
Normalized: aurora ev icd mri surescan
Device Medtronic, Inc. $137.40 5 2025
Source payment records
WATCHMAN FLX
Normalized: watchman flx
Device Boston Scientific Corporation $131.08 2 2025
Source payment records
Soundstar
Normalized: soundstar
Device Biosense Webster, Inc. $130.70 3 2025
Source payment records
ENSITE
Normalized: ensite
Device Abbott Laboratories $79.23 1 2025
Source payment records
THORATEC HEARTMATE 3 LVAS IMPLANT KIT
Normalized: thoratec heartmate 3 lvas implant kit
Device Abbott Laboratories $44.28 2 2025
Source payment records
TRICLIP
Normalized: triclip
Device Abbott Laboratories $44.00 1 2025
Source payment records
LINQ II
Normalized: linq ii
Device Medtronic, Inc. $43.00 5 2025
Source payment records
OMNIASECURE MRI SURESCAN
Normalized: omniasecure mri surescan
Device Medtronic, Inc. $23.73 1 2025
Source payment records
CARDIOMEMS
Normalized: cardiomems
Device Abbott Laboratories $22.72 1 2025
Source payment records
CARDIVA VASCADE 6/7F VCS
Normalized: cardiva vascade 6 7f vcs
Device CARDIVA MEDICAL, INC. $22.29 1 2025
Source payment records
COBALT DR MRI SURESCAN
Normalized: cobalt dr mri surescan
Device Medtronic, Inc. $16.24 1 2025
Source payment records
PERCLOSE PROSTYLE
Normalized: perclose prostyle
Device Abbott Laboratories $13.17 1 2025
Source payment records
MYCARELINK
Normalized: mycarelink
Device Medtronic, Inc. $7.62 1 2025
Source payment records
MICRA
Normalized: micra
Device Medtronic, Inc. $6.87 1 2025
Source payment records
CAPSUREFIX NOVUS MRI SURESCAN
Normalized: capsurefix novus mri surescan
Device Medtronic, Inc. $2.10 1 2025
Source payment records
EVERA MRI XT DR SURESCAN
Normalized: evera mri xt dr surescan
Device Medtronic, Inc. $1.93 1 2025
Source payment records

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

YearGeneral PaymentsMain payerExplicit productsCompany overlapsPart D coverage
2025 $5,778.22 · 71 records Medtronic, Inc. AMPLATZER AMULET, AURORA EV-ICD MRI SURESCAN, AVEIR, AZURE XT DR MRI SURESCAN, CAPSUREFIX NOVUS MRI SURESCAN, CARDIOMEMS, CARDIVA VASCADE 6/7F VCS, CARTO 3, COBALT DR MRI SURESCAN, DERMABOND PRINEO, ENSITE, ETHICON, EVERA MRI XT DR SURESCAN, FARAPULSE, General - Therapies, LINQ II, MICRA, MYCARELINK, OMNIASECURE MRI SURESCAN, PERCLOSE PROSTYLE, QDOT MICRO, STRATAFIX, Soundstar, THORATEC HEARTMATE 3 LVAS IMPLANT KIT, TRICLIP, VISTASEAL, VersaCross Access Solution, WATCHMAN FLX
2024 Complete

Questions to ask

Questions you could discuss with your doctor

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Loaded source releases

DatasetYearPublicationSource
CMS Open Payments — General Payments 2025 2026-06-30 Original source
Medicare Part D Prescribers by Provider and Drug 2024 2026-05-06 Original source
NPPES Data Dissemination V2 current / reference data 2026-08-10 Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error